Charles River generated best-in-class data with Kytopen’s Flowfect™ technology in comparative study. The study using CRISPR/Cas9 TRAC gene knockout experiments in primary T cells revealed that the Flowfect Tx™ platform delivers greater cell viability and editing efficiency compared to…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.